Cargando…
Hochhaus et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood. 2008;111:1039-1043.
| Formato: | Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
American Society of Hematology
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2464565/ http://dx.doi.org/10.1182/blood-2008-05-158873 |
| _version_ | 1782157421681049600 |
|---|---|
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2464565 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2008 |
| publisher | American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-24645652009-07-15 Hochhaus et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood. 2008;111:1039-1043. Blood Erratum American Society of Hematology 2008-07-15 /pmc/articles/PMC2464565/ http://dx.doi.org/10.1182/blood-2008-05-158873 Text en © 2008 by The American Society of Hematology |
| spellingShingle | Erratum Hochhaus et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood. 2008;111:1039-1043. |
| title | Hochhaus et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood. 2008;111:1039-1043. |
| title_full | Hochhaus et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood. 2008;111:1039-1043. |
| title_fullStr | Hochhaus et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood. 2008;111:1039-1043. |
| title_full_unstemmed | Hochhaus et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood. 2008;111:1039-1043. |
| title_short | Hochhaus et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood. 2008;111:1039-1043. |
| title_sort | hochhaus et al. favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. blood. 2008;111:1039-1043. |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2464565/ http://dx.doi.org/10.1182/blood-2008-05-158873 |